RSV604 racemate is primarily investigated for its antiviral properties, particularly in the treatment of respiratory syncytial virus (RSV) infections. It functions as an inhibitor of viral replication, targeting specific proteins or enzymes essential for the virus's lifecycle. This compound has shown potential in clinical studies for reducing viral load and improving symptoms in patients with RSV, especially in high-risk groups such as infants, the elderly, and immunocompromised individuals. Its application extends to both therapeutic and prophylactic uses, aiming to prevent severe respiratory complications associated with RSV infections. Research continues to explore its efficacy, safety, and potential for combination therapies with other antiviral agents.